About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Care and Law
A closely watched legal decision raises the question of whether companies will be able to protect their ownership of genetic information.
Robert I. Field, JD, MPH, PhD
A Practical Review for Pharmacists
Dr. Craig describes the drug’s pharmacology, pharmacokinetics, efficacy, and safety; the process of switching from other agents; and ways pharmacists can help prevent abuse of this controlled substance.
David S. Craig, PharmD, BCPS
American Academy of Neurology, 62nd Annual Meeting and American Society of Hypertension, 25th Annual Scientific Meeting and Exposition
Neurology topics include Guillain-Barré syndrome after H1N1 vaccine administration, sodium oxybate for fibromyalgia, and botulinum neurotoxin type A (NT-201) for dystonias. Angiotensin-receptor blocker combinations for hypertension include phentermine/topiramate, amlodipine/olmesartan, and chlorthalidone/azilsartan.
Sipuleucel-T (Provenge) for prostate cancer, polidocanol (Asclera) for varicose veins, and imiquimod cream 3.75% (Zyclara) for actinic keratoses are discussed.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
A chronic inflammation of the skin, seborrheic dermatitis affects more than 11% of people and almost 70% of infants. The authors discuss various drug and non-drug therapies and the role of the pharmacist in counseling patients about this condition and its treatment.
Thomas Berk, MD, and Noah Scheinfeld, MD
A former American President has inspired our editor-in-chief to reflect on our global economy and interdependence.
David B. Nash, MD, MBA
Preventing catastrophic events requires transforming the culture of patient safety.
Matthew Grissinger, RPh, FASCP
Stephen Barlas explains why many pharmacists are not being helped by the FDA’s latest guidance on authenticating drug packages.
P&T presents FDA approvals, drug indications, product recalls, and devices in the news.
Immediate-release tapentadol (Nucynta) for moderate-to-severe pain is discussed.
Bazhena Fidman, PharmD Candidate, and Anna Nogid, BS, PharmD, BCPS